Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.